14 February 2019 in Journal of the European Academy of Dermatology and Venereology
1 April 2021 in Journal of Investigative Dermatology
17 January 2022 in Journal of Investigative Dermatology
9 February 2022 in Clinical Cancer Research
Purpose: An increased risk to develop cancer is one of the most challenging negative side effects of long-term immunosuppression in organ transplant recipients and impaired cancer immunosurveillance is assumed as underlying mechanism. This study aims to elucidate transplant-related changes in the tumor immune microenvironment (TME) of cancer. Experimental Design: Data from 123 organ transplant recipients (kidney, heart, lung, and liver) were compared with historic data from non-immunosuppressed patients. Digital image analysis of whole-section slides was used to assess abundance and spatial distribution of T cells and tertiary lymphoid structures (TLS) in the TME of 117 tumor samples. Expression of programmed cell death 1 ligand 1 (PD-L1) and human-leucocyte-antigen class I (HLA-I) was assessed on tissue microarrays. Results: We found a remarkably reduced immune infiltrate in the center tumor (CT) regions as well as the invasive margins (IM) of post-transplant cancers. These differences were more pronounced in the IM than in the CT and larger for CD8+ T cells than for CD3+ T cells. The Immune-score integrating results from CT and IM was also lower in transplant recipients. Density of TLS was lower in cancer samples of transplant recipients. The fraction of samples with PD-L1 expression was higher in controls whereas decreased expression of HLA-I was more common in transplant recipients. Conclusions: Our study demonstrates the impact of immunosuppression on the TME and supports impaired cancer immunosurveillance as important cause of post-transplant cancer. Modern immunosuppressive protocols and cancer therapies should consider the distinct immune microenvironment of post-transplant malignancies.
4 April 2025 in Journal of the European Academy of Dermatology and Venereology
Background: Immune‐checkpoint inhibitor (ICI) therapy elicits durable responses in a subset of patients with advanced melanoma. However, the appropriate timing for treatment cessation remains an unresolved issue. Moreover, some patients are required to discontinue therapy due to the occurrence of severe adverse events. Upon treatment cessation, a subset of patients maintains a durable response, while some patients relapse and require rechallenge with ICI. Criteria for a safe stop of ICI have not been established. Objectives: The aim of this systematic review and meta‐analysis was to evaluate the durability of response in melanoma patients who discontinued ICI therapy. Furthermore, the outcome of patients who electively stopped therapy was compared to that of patients who discontinued therapy due to adverse events. Methods: MEDLINE/PubMed, Embase and the Cochrane Library were searched for studies reporting outcomes after ICI discontinuation in patients with advanced melanoma. Pooled 1‐ to 3‐year progression‐free survival (PFS) and overall survival (OS) rates were estimated using random‐effects models. The impact of the reason for treatment discontinuation, therapy regime and treatment duration on relapse‐free survival was evaluated. Results: Twenty studies including 1832 patients were analysed. The pooled 1‐ and 3‐year PFS rates after therapy stop were 86% (95% CI 80%–91%) and 71% (95% CI 64%–77%). A significantly higher 1‐year PFS rate was observed in patients who electively discontinued treatment in contrast to toxicity‐related therapy cessation (91% vs. 79%). Longer ICI treatment was associated with a higher PFS rate. 1‐ and 3‐year OS rates post ICI treatment discontinuation were 96% (95% CI 91%–99%) and 86% (95% CI 79%–92%). Conclusions: Most patients remained relapse‐free after ICI treatment. Patients with a treatment duration of at least 2 years are ideal candidates for treatment cessation, while treatment discontinuation may be considered after at least 1 year of ICI. PROSPERO number: CRD42024543781.
19 September 2018 in International Journal of Dermatology